Lexicon Pharmaceuticals Inc. announced the results of a post-hoc analysis demonstrating that the addition of sotagliflozin to optimized insulin therapy reduces the risk of clinically important hypoglycemic events in adults with Type 1 Diabetes. These findings were presented at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, Illinois. The analysis evaluated the effect of kidney function on hypoglycemia risk, using pooled data from inTandem 1 and inTandem 2 Phase 3 clinical trials. The results indicated that sotagliflozin reduces hypoglycemia events, particularly in patients with blood glucose levels ≤55 mg/dL, across various kidney function subgroups without increasing the risk of severe hypoglycemia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。